专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1998013484A1 TWO HUMAN CATHEPSIN PROTEINS 审中-公开
标题翻译：两种人类蛋白质蛋白
公开(公告)号：WO1998013484A1
公开(公告)日：1998-04-02
申请号：PCT/US1997017175
申请日：1997-09-25
申请人： INCYTE PHARMACEUTICALS, INC. , BANDMAN, Olga , COLEMAN, Roger
发明人： INCYTE PHARMACEUTICALS, INC.
IPC分类号： C12N09/64
CPC分类号： G01N33/573 , A61K38/00 , C12N9/6421 , C12N9/6478 , G01N2333/96413 , G01N2500/02
摘要： The present invention provides two novel human cathepsin proteins (HCPs) and polynucleotides encoding HCPs. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HCPs. The invention also provides for the production and use of antibodies to HCPs in pharmaceutical compositions for the treatment of disease processes that include cancers, inflammation, metastasis and peptide and proenzyme processing. In addition, the invention provides for the production and use of inhibitors of HCPs in pharmaceutical compositions for the treatment of diseases. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HCPs. The invention also provides for the use of antisense molecules in pharmaceutical compositions as therapeutics in cancers, inflammation, metastasis and peptide and proenzyme processing.
摘要翻译：本发明提供两种新的人组织蛋白酶蛋白（HCP）和编码HCP的多核苷酸。本发明提供了包含编码HCP的核酸序列的基因工程表达载体和宿主细胞。本发明还提供用于治疗包括癌症，炎症，转移和肽以及酶原处理的疾病过程的药物组合物中HCP抗体的生产和使用。此外，本发明提供了用于治疗疾病的药物组合物中HCP抑制剂的生产和使用。本发明还描述了利用多核苷酸与编码HCP的转录物杂交的诊断测定法。本发明还提供了药物组合物中的反义分子在癌症，炎症，转移和肽和酶原处理中的用途。

2. 发明申请

WO1997032015A1 METHOD OF PURIFYING THROMBIN-LIKE PROTEASE ENZYMES OBTAINED FROM SNAKE VENOM 审中-公开
标题翻译：程序从蛇毒中凝血酶清洗蛋白酶
公开(公告)号：WO1997032015A1
公开(公告)日：1997-09-04
申请号：PCT/EP1997000755
申请日：1997-02-18
申请人： KNOLL AKTIENGESELLSCHAFT , SCHWARZ, Margarete , ZAHN, Wolfgang
发明人： KNOLL AKTIENGESELLSCHAFT
IPC分类号： C12N09/64
CPC分类号： C12N9/6418 , Y10S435/814 , Y10S435/815
摘要： Described is a method of purifying thrombin-like protease enzymes from snake venom, the method consisting of freeing the enzymes of impurities in three chromatographic stages.
摘要翻译：提供了一种用于净化从描述蛇毒，这是它释放以杂质三个色谱步骤的蛋白酶凝血酶样蛋白酶的方法。

3. 发明申请

WO1997004080A1 NOVEL PROTEIN AND MONOCLONAL ANTIBODY SPECIFIC THERETO 审中-公开
标题翻译：新型蛋白质和单克隆抗体特异性
公开(公告)号：WO1997004080A1
公开(公告)日：1997-02-06
申请号：PCT/JP1996001956
申请日：1996-07-12
申请人： FUJI YAKUHIN KOGYO KABUSHIKI KAISHA , SEIKI, Motoharu , SATO, Hiroshi , SHINAGAWA, Akira
发明人： FUJI YAKUHIN KOGYO KABUSHIKI KAISHA
IPC分类号： C12N09/64
CPC分类号： C12N9/6491 , A61K38/00 , C07K16/40 , Y02A50/473
摘要： A novel protein which is useful as diagnostic means for the studies relating to the diagnosis and treatment of cancer (detection of cancer cells, estimation of the malignity, etc.) and in other medicinal and physiological purposes; a gene encoding the same; and an antibody, in particular, a monoclonal antibody specific to the protein. MT-MMP-3, which is a latent MMP-2 activator having the ability to activate latent MMP-2 which is under expression specifically on the surface layer of a human cancer cell and falling within the category of MMP but being different from MT-MMP-1; a DNA containing the base sequence encoding the same; host cells transformed by the DNA; a process for producing a matrix metalloprotease protein by using the host cells; a monoclonal antibody binding specifically to the matrix metalloprotease protein; and use of the protein and antibody.
摘要翻译：一种新的蛋白质，可用于诊断和治疗癌症（癌症细胞的检测，恶性肿瘤的估计等）和其他药物和生理学目的的诊断手段; 编码该基因的基因; 特别是抗体，特别是针对蛋白质的单克隆抗体。 MT-MMP-3是潜在的MMP-2激活剂，其具有活化潜在的MMP-2的能力，其潜在的MMP-2在人类癌细胞的表面上特异性地表达，并且属于MMP类别，但不同于MT- MMP-1; 含有编码其的碱基序列的DNA; 由DNA转化的宿主细胞; 通过使用宿主细胞产生基质金属蛋白酶蛋白的方法; 特异性结合基质金属蛋白酶蛋白的单克隆抗体; 并使用蛋白质和抗体。

4. 发明申请

WO1996027003A1 A PROCESS FOR THE PREPARATION OF FACTOR IX FROM BIOLOGICAL SOURCES 审中-公开
标题翻译：一个从生物来源制备因子IX的过程
公开(公告)号：WO1996027003A1
公开(公告)日：1996-09-06
申请号：PCT/EP1996000636
申请日：1996-02-14
申请人： OCTAPHARMA AG , JOSIC, Djuro , HOFFER, Lutz , MORFELD, Frank
发明人： OCTAPHARMA AG
IPC分类号： C12N09/64
CPC分类号： C12N9/644 , C12Y304/21022
摘要： A process for the preparation of factor IX from biological sources by chromatography, characterized in that prior to any chromatographic separations said source is treated with a protein precipitant.
摘要翻译：用于通过色谱法从生物来源制备因子IX的方法，其特征在于在任何色谱分离之前，所述来源用蛋白质沉淀剂处理。

5. 发明申请

WO1996001312A1 NON-GLYCOSYLATED PLASMINOGEN ACTIVATOR DERIVATIVES AND THEIR USE IN CONDITIONS INVOLVING A HIGH RISK OF BLEEDING 审中-公开
标题翻译：非糖基化蛋白溶酶原衍生物及其出血风险增加
公开(公告)号：WO1996001312A1
公开(公告)日：1996-01-18
申请号：PCT/EP1995002391
申请日：1995-06-20
申请人： BOEHRINGER MANNHEIM GMBH , KOHNERT, Ulrich , STERN, Anne , MARTIN, Ulrich , FISCHER, Stephan
发明人： BOEHRINGER MANNHEIM GMBH
IPC分类号： C12N09/64
CPC分类号： C12N9/6459 , A61K38/00 , C12Y304/21069
摘要： The invention concerns a non-glycosylated tissue plasminogen activator derivative which contains the essential parts of at least one Kringle domain and a B-chain with serine protease activity of the tissue plasminogen activator and which is characterized in that each of the amino-acids 296 to 299 (Lys-His-Arg-Arg) is replaced by alanine. Owing to the low risk of bleeding associated with its use, this derivative is particularly suitable for use in the treatment of subchronic thromboembolic disorders.
摘要翻译：其含有至少一个三环域和所述主要部分与组织纤溶酶原激活的丝氨酸蛋白酶活性的B链和非糖基化的组织纤溶酶原激活衍生物的特征在于，在针对每一种情况下的氨基酸296-299（赖氨酸组氨酸 - 精氨酸 - 精氨酸）丙氨酸被替换，由于出血的风险低是特别适用于亚慢性血栓栓塞性病症的治疗。

6. 发明申请

WO1994006906A1 DNA ENCODING MURINE PRECURSOR INTERLEUKIN 1'beta' CONVERTING ENZYME 审中-公开
标题翻译： DNA编码MURINE前体INTERLEUKIN 1 beta转化酶
公开(公告)号：WO1994006906A1
公开(公告)日：1994-03-31
申请号：PCT/US1993008479
申请日：1993-09-09
申请人： MERCK & CO., INC. , MOLINEAUX, Susan, M. , ROLANDO, Anna, Maria , CASANO, Francesca, J.
发明人： MERCK & CO., INC.
IPC分类号： C12N09/64
CPC分类号： C12N9/6475
摘要： Complementary DNA (cDNA) encoding the murine precursor interleukin-1 beta (pre-IL-1 beta ) converting enzyme (ICE) is isolated from a murine cDNA library. A cDNA, encoding the full-length open reading frame (ORF) for the nascent ICE as well as the 20 kDa subunit and the 10 kDa subunit of ICE are identified and sequenced. ICE is useful in the conversion of pre-IL-1 beta into mature IL-1 beta . The murine ICE cDNA is useful in obtaining the genomic sequence. The recombinantly produced murine ICE is useful in the identification of inhibitors of ICE activity.
摘要翻译：从鼠cDNA文库中分离编码鼠前体白细胞介素-1β（前IL-1β）转换酶（ICE）的互补DNA（cDNA）。鉴定并测序编码新生ICE的全长开放阅读框（ORF）以及ICE的20kDa亚基和10kDa亚基的cDNA。 ICE可以将IL-1β转化成成熟IL-1β。鼠ICE cDNA可用于获得基因组序列。重组产生的鼠ICE可用于鉴定ICE活性抑制剂。

7. 发明申请

WO1993022429A1 NOVEL COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF HUMAN OSTEOARTHRITIS 审中-公开
标题翻译：新型组合物和人类骨质疏松症检测和治疗方法
公开(公告)号：WO1993022429A1
公开(公告)日：1993-11-11
申请号：PCT/US1993004029
申请日：1993-04-29
申请人： SHRINERS HOSPITALS FOR CRIPPLED CHILDREN
发明人： SHRINERS HOSPITALS FOR CRIPPLED CHILDREN , SANDY, John, D. , FLANNERY, Carl, R. , NEAME, Peter, J. , LOHMANDER, L., Stefan
IPC分类号： C12N09/64
CPC分类号： G01N33/6887 , A61K38/55 , A61K39/3955 , C07K14/4725 , C12N9/6421 , G01N2800/105
摘要： The subject invention concerns novel materials and methods for the detection, treatment, and prevention of human osteoarthritis. Specifically, the cleavage site where aggrecanase cleaves aggrecan has been identified. Identification of this site, as well as the nature of the enzyme, facilitates specific treatments which block or diminish the activity of the enzyme. A further aspect of the invention concerns methods for detecting evidence of osteoarthritis.
摘要翻译：本发明涉及用于检测，治疗和预防人类骨关节炎的新型材料和方法。具体地，已经鉴定了聚蛋白聚糖蛋白聚糖酶切割聚集蛋白聚糖的切割位点。该位点的鉴定以及酶的性质有助于阻断或降低酶活性的特异性处理。本发明的另一方面涉及用于检测骨关节炎证据的方法。

8. 发明申请

WO1991015576A1 TREATMENT OF THROMBOTIC EVENTS 审中-公开
标题翻译：治疗血栓事件
公开(公告)号：WO1991015576A1
公开(公告)日：1991-10-17
申请号：PCT/GB1991000549
申请日：1991-04-08
申请人： BIOPHARM (UK) LIMITED , SAWYER, Roy, T. , POWELL-JONES, Christopher , ATKINSON, Anthony , ELECTRICWALA, Asgar
发明人： BIOPHARM (UK) LIMITED
IPC分类号： C12N09/64
CPC分类号： C12N9/6402 , A61K38/00
摘要： A method of treatment of thrombotic events which comprises administering a therapeutically effective amount of a pharmaceutical formulation comprising hementin or a material capable of preferentially cleaving between the D and E domains of the fibrinogen linkages present in platelet aggregates, in such an amount and in such a manner as to dissolve a clot which predominantly comprises, by volume, platelet aggregates.
摘要翻译：一种治疗血栓事件的方法，其包括施用治疗有效量的药物制剂，所述药物制剂包含海伦蛋白或能够在血小板聚集体中存在的纤维蛋白原连接的D和E结构域之间优先切割的材料，方式溶解主要包含体积的血小板聚集体的凝块。

9. 发明申请

WO1990010062A1 METASTASIS-ASSOCIATED COLLAGENOLYTIC METALLOPROTEINASES 审中-公开
标题翻译： METASTASIS相关的胶原蛋白金属蛋白酶
公开(公告)号：WO1990010062A1
公开(公告)日：1990-09-07
申请号：PCT/US1990000506
申请日：1990-01-29
申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , NAKAJIMA, Motowa , NICOLSON, Garth, L.
IPC分类号： C12N09/64
CPC分类号： C12N9/6491 , C07K16/40
摘要： Disclosed are methods and compositions for testing for various types of human cancers, including in particular metastatic mammary carcinoma, colon carcinoma astrocytoma, renal cell carcinoma, and teratocarcinoma malignant melanoma. The diagnostic method of the invention involves the detection of a gelatinolytic and type IV collagenolytic metalloproteinase having molecular weight of approximately 88 to 92 kilodaltons in size. This high molecular weight type IV collagenolytic enzyme is found to be associated with the cancerous state, but this has not been found in any noncancerous cells tested and further not found in the serum of non tumor bearing animals. The enzyme is associated both with rat and human tumors, the enzyme in each case being quite similar. Methods are disclosed for isolating the 88/92 kd enzyme, the isolated enzyme being useful as a control enzyme and diagnostic assays. Furthermore, the isolated enzyme will be useful in the preparation of antibodies, including monoclonal antibodies, having specificity for the metastasis-associated enzyme. Techniques are also disclosed for isolation and partial purification of the enzyme from both rat and human sources. Furthermore, methods are disclosed for conducting both enzymatic and immunologic based tests for the diagnosis of metastatic and recurrent disease.
摘要翻译：公开了用于测试各种类型的人类癌症的方法和组合物，包括特别是转移性乳腺癌，结肠癌星形细胞瘤，肾细胞癌和畸胎癌恶性黑素瘤。本发明的诊断方法涉及检测分子量约88至92千道尔顿的明胶分解和IV型胶原蛋白溶解金属蛋白酶的大小。发现这种高分子量IV型胶原分解酶与癌症状态相关，但是在所测试的任何非癌细胞中还没有发现，并且在非肿瘤携带动物的血清中还没有发现。该酶与大鼠和人类肿瘤相关，每种情况下的酶非常相似。公开了用于分离88/92kD酶的方法，所述分离的酶可用作对照酶和诊断测定。此外，分离的酶将可用于制备对转移相关酶具有特异性的抗体，包括单克隆抗体。还公开了从大鼠和人源分离和部分纯化酶的技术。此外，公开了用于进行用于诊断转移性和复发性疾病的基于酶学和免疫学的测试的方法。

10. 发明申请

WO1990004635A1 THROMBOLYTIC AGENTS WITH MODIFIED KRINGLE DOMAINS 审中-公开
标题翻译：具有修改的KRINGLE域的热致变色剂
公开(公告)号：WO1990004635A1
公开(公告)日：1990-05-03
申请号：PCT/US1989004247
申请日：1989-10-04
申请人： THE UPJOHN COMPANY , HATZENBUHLER, Nicole, T. , MAROTTI, Keith, R. , REHBERG, Edward, F. , VERHEIJEN, Johan, H.
发明人： THE UPJOHN COMPANY
IPC分类号： C12N09/64
CPC分类号： C12N9/6456 , A61K38/00
摘要： This invention is related to analogs of thrombolytic agents having a modified kringle domain. More specifically this invention is directed to TPA type compounds wherein modifications in the kringle 1 and kringle 2 domains occur. This invention is also directed to analogs with one or more changes in the kringle domain of urokinase-type compounds. The compounds of this invention are pharmaceutically useful having particular use in the same manner as TPA and urokinase.
摘要翻译：本发明涉及具有改良的三环结构域的溶栓剂类似物。更具体地，本发明涉及TPA型化合物，其中发生kringle 1和kringle 2结构域的修饰。本发明还涉及在尿激酶型化合物的三环结构域中具有一个或多个变化的类似物。本发明的化合物在药学上是有用的，其具体用途与TPA和尿激酶相同。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式